Home » Topics » BioWorld Science

BioWorld Science
RSS

New MAP2K inhibitors discovered at Immuneering Corp.

Aug. 5, 2021

Merck & Co. identifies new arginase inhibitors

Aug. 5, 2021

PanTher receives ethics approval to initiate phase I study of PTM-101 in Australia

Aug. 5, 2021

FDA clears IND for [225Ac]PSMA I&T for mCRPC

Aug. 5, 2021

Allergy Therapeutics reports findings from ex vivo biomarker study of VLP Peanut

Aug. 5, 2021

RGS10 gene mutations linked to combined immunodeficiency

Aug. 5, 2021

Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies

Aug. 5, 2021

Qurient initiates phase II study of telacebec in moderate COVID-19

Aug. 5, 2021

New study is both reality check and shot in the arm for SARS-CoV-2 drug repurposing

Aug. 4, 2021

Phase IIb/III ALLEGRO trial of ritlecitinib in alopecia areata meets primary efficacy endpoint

Aug. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...